Literature DB >> 12221586

Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I induction of transforming growth factor beta1 and c-myc in liver with marginal effects on other genes.

Quanren He1, Marcin F Osuchowski, Victor J Johnson, Raghubir P Sharma.   

Abstract

Silymarin, a mixture of flavonolignans isolated from Silybum marianum, is known for its hepatoprotective properties. We investigated the expression of cytokines in mouse liver following treatment with 0, 10, 50, and 250 mg/kg of silymarin once daily for 5 days. A dose-related but insignificant decrease of circulating alanine aminotransferase and aspartate aminotransferase after silymarin treatment was observed, suggesting that silymarin treatment did not induce hepatic damage. Silymarin treatment caused significant increases in the expressions of transforming growth factor (TGF) beta1 and c-myc in liver. No significant difference was detected among these treatments in the expression of hepatocyte growth factor, interferon gamma, tumor necrosis factor alpha, and class II major histocompatibility complex. These results suggest that alterations of TGFbeta1 and c-myc expression in the liver may be involved in the hepatoprotective effects of silymarin observed in other studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12221586     DOI: 10.1055/s-2002-33801

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  4 in total

1.  Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis.

Authors:  Hílton Antônio Mata-Santos; Fabianno Ferreira Dutra; Carolina Carneiro Rocha; Fabiana Gonçalves Lino; Fabiola Ramos Xavier; Leandro Andrade Chinalia; Bryan Hudson Hossy; Morgana Teixeira Lima Castelo-Branco; Anderson Junger Teodoro; Claudia N Paiva; Alexandre dos Santos Pyrrho
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

2.  Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis.

Authors:  Hílton Antonio Mata-Santos; Fabiana Gonçalves Lino; Carolina Carneiro Rocha; Claudia Neto Paiva; Morgana Teixeira Lima Castelo Branco; Alexandre dos Santos Pyrrho
Journal:  Parasitol Res       Date:  2010-08-07       Impact factor: 2.289

Review 3.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

4.  Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation.

Authors:  Shengyu Xu; Xiaojun Jiang; Xinlin Jia; Xuemei Jiang; Lianqiang Che; Yan Lin; Yong Zhuo; Bin Feng; Zhengfeng Fang; Jian Li; Jianping Wang; Zhihua Ren
Journal:  Animals (Basel)       Date:  2022-08-26       Impact factor: 3.231

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.